LucasBio: Clinical Trials

7 trials sponsored by LucasBio, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 4 Not applicable, 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Not applicable4Completed 2, Recruiting 2
Phase 13Active not recruiting 1, Not yet recruiting 1, Recruiting 1
Phase 22Not yet recruiting 1, Recruiting 1

Follow LucasBio: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation
LB-DTK-BKV, Standard-of-care - Hemorrhagic Cystitis
Phase 1 / Phase 2Not yet recruitingLucasBio422026-09-012026-07-24
Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
LB-DTK-CMV - CMV Retinitis
Not applicableRecruitingLucasBio52026-04-272026-07-01
Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
LB-DTK-MV - BKV Infection, CMV Infection
Not applicableRecruitingLucasBio62026-02-102026-07-06
Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.
LB-DTK-MV - BKV Infection, EBV Infection
Phase 1 / Phase 2RecruitingLucasBio272025-12-042026-06-26
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients
LB-DTK-COV19 - COVID-19, COVID-19 (SARS-CoV-2 Infection)
Phase 1Active not recruitingLucasBio12025-07-312026-08-26
Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients
LB-DTK-COV19 - COVID-19, COVID-19 (SARS-CoV-2 Infection)
Not applicableCompletedLucasBio132023-06-082026-07-08
Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.
CIK cells - Autologous Hematopoietic Stem Cell Transplant
Not applicableCompletedLucasBio252022-03-282026-07-09

Conditions studied

Infections (5)  ·  Virus Diseases (5)  ·  COVID-19 (2)  ·  Cytomegalovirus Infections (2)  ·  Epstein-Barr Virus Infections (2)  ·  Hematologic Neoplasms (2)  ·  Autoimmune Diseases (1)  ·  Cystitis (1)  ·  Cystitis, Hemorrhagic (1)  ·  Cytomegalovirus Retinitis (1)  ·  Lymphoma (1)  ·  Neoplasm, Residual (1)  ·  Pneumonia (1)  ·  Retinitis (1)  ·  Signs and Symptoms, Respiratory (1)

Interventions

Standard of Care (1)

Countries

South Korea (7)

Top investigators

Dong-Gun Lee, MD-PhD (2)  ·  Eun Sun Yoo, MD-PhD (1)  ·  Ho-joon Im, MD-PhD (1)  ·  Hoon Kook, MD-PhD (1)  ·  Hyeon Jin Park, MD-PhD (1)  ·  Hyoung Jin Kang, MD-PhD (1)  ·  Jae-Cheol Jo, MD-PhD (1)  ·  Jae-won Yoo, MD-PhD (1)  ·  Joonho Moon, MD-PhD (1)  ·  Rae Seok Lee, MD-PhD (1)  ·  Seok-Goo Cho, MD-PhD (1)  ·  Seung Min Hahn, MD-PhD (1)  ·  Yae-Jean Kim, MD-PhD (1)  ·  Young Hoon Park, MD-PhD (1)

Results publications

PMID 40493744, PMID 41520915